Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Navigation/Suche
- Forscher*innen
- Institutionen
- Projekte
- Publikationen
- Partner
- Geldgeber
- Ausstattung
- Knowhow
- Forschungsfelder
"Köpfe" der aktuellen Meldungen:
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Stojakovic, T; Claudel, T; Putz-Bankuti, C; Fauler, G; Scharnagl, H; Wagner, M; Sourij, H; Stauber, RE; Winkler, K; März, W; Wascher, TC; Trauner, M.
Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment.
Atherosclerosis. 2010; 209(1): 178-183.
Doi: 10.1016/j.atherosclerosis.2009.08.052
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Führende Autor*innen der Med Uni Graz
- Stojakovic Tatjana
- Trauner Michael
- Co-Autor*innen der Med Uni Graz
- Claudel Thierry
- Fauler Günter
- März Winfried
- Putz-Bankuti Csilla
- Scharnagl Hubert
- Sourij Harald
- Stauber Rudolf
- Wagner Martin
- Wascher Thomas
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Objective: Primary biliary cirrhosis (PBC) is frequently associated with hypercholesterolemia and with an increased cardiovascular morbidity and mortality. Statins lower serum cholesterol levels and may thus improve the cardiovascular risk in PBC patients. The aim of our study was to prospectively examine the efficacy of low-dose atorvastatin on cholestasis as well as cardiovascular risk markers such as dyslipidemia and vascular function in patients with PBC. Methods: Nineteen patients with early-stage (biopsy proven and AMA positive) PBC and low-density lipoprotein cholesterol (LDL-C) above 130 mg/dL were included in this single-center study and treated with atorvastatin 10 mg per day for one year. Results: Concentrations of total cholesterol, LDL-C, LDL triglycerides, oxLDL, IgG and sVCAM-1 decreased significantly after 48 weeks of atorvastatin treatment. Flow-mediated dilation (FMD) of the brachial artery as an indicator of vascular function significantly increased, while carotid artery intima-media thickness and vascular wall stiffness did not progress under treatment. No statistical differences in liver enzymes were observed except a transient increase of alkaline phosphatase. Conclusion: Treatment with low-dose atorvastatin is safe in early-stage PBC, effectively reduces total cholesterol, LDL-C, LDL triglycerides, oxLDL and sVCAM-1 and improves vascular function as reflected by FMD, without affecting cholestasis progression. Therefore, statin therapy should be considered in PBC patients with additional risk factors for cardiovascular disease. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
- Find related publications in this database (using NLM MeSH Indexing)
- Blood Vessels - drug effects Blood Vessels - physiopathology
- Cardiovascular Diseases - etiology Cardiovascular Diseases - prevention and control
- Cholestasis - etiology Cholestasis - physiopathology
- Cholesterol - blood
- Female -
- Heptanoic Acids - administration and dosage
- Humans -
- Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration and dosage
- Hypercholesterolemia - blood Hypercholesterolemia - drug therapy Hypercholesterolemia - etiology
- Liver Cirrhosis, Biliary - complications Liver Cirrhosis, Biliary - physiopathology
- Male -
- Middle Aged -
- Prospective Studies -
- Pyrroles - administration and dosage
- Find related publications in this database (Keywords)
- Atherosclerosis
- Cholestasis
- Hypercholesterolemia
- Primary biliary cirrhosis
- Statins
- Vascular function